Results 41 to 50 of about 276,656 (346)

Evaluate the prevalence of CCP and RF antibodies as a marker for diagnosis and progression of Rheumatoid Arthritis disease and assess the prevalence of HCV in RA patients [PDF]

مجلة جامعة الانبار للعلوم الصرفة, 2014
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease characterized by the presence of autoantibodies like rheumatoid factor (RF). In the last few years, several other autoantibodies have been described of which anti-cyclic citrullinated
Qabas R. Ali, Mohammad Q. Alani, Hanaa N. Abdallha, Salim Obaid Al Mawla   +3 more
doaj   +1 more source

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.

New England Journal of Medicine, 2015
BACKGROUND In phase 2 trials, treatment with the combination of the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor velpatasvir resulted in high rates of sustained virologic response in patients chronically infected with hepatitis C ...
G. Foster, N. Afdhal, S. Roberts, N. Bräu, E. Gane, S. Pianko, E. Lawitz, A. Thompson, M. Shiffman, C. Cooper, W. Towner, B. Conway, P. Ruane, M. Bourlière, T. Asselah, T. Berg, S. Zeuzem, W. Rosenberg, K. Agarwal, C. Stedman, H. Mo, H. Dvory‐Sobol, Lingling Han, Jing Wang, J. McNally, A. Osinusi, D. Brainard, J. Mchutchison, F. Mazzotta, T. Tran, S. Gordon, K. Patel, N. Reau, A. Mangia, M. Sulkowski   +34 more
semanticscholar   +1 more source

LncRNAs in HCV Infection and HCV-Related Liver Disease [PDF]

International Journal of Molecular Sciences, 2020
Long non-coding RNAs (lncRNAs) are transcripts with poor coding capacity that may interact with proteins, DNA, or other RNAs to perform structural and regulatory functions. The lncRNA transcriptome changes significantly in most diseases, including cancer and viral infections.
Juan P. Unfried, P. Fortes
openaire   +2 more sources

Attacking the public health crisis of hepatocellular carcinoma at its roots

Hepatology, EarlyView., 2022
Abstract As the third most common cause of cancer‐related death worldwide with significant mortality rates in the United States, hepatocellular carcinoma has strong association with cirrhosis and chronic hepatitis B virus (HBV) with a growing at‐risk population from the rise in chronic liver disease from alcohol use and nonalcoholic fatty liver disease.
Hannah M. Lee, Steven D. Lidofsky, Tamar H. Taddei, Lisa J. Townshend‐Bulson   +3 more
wiley   +1 more source

Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.

New England Journal of Medicine, 2014
BACKGROUND High rates of sustained virologic response were observed among patients with hepatitis C virus (HCV) infection who received 12 weeks of treatment with the nucleotide polymerase inhibitor sofosbuvir combined with the NS5A inhibitor ledipasvir ...
K. Kowdley, S. Gordon, K. Reddy, L. Rossaro, D. Bernstein, E. Lawitz, M. Shiffman, E. Schiff, R. Ghalib, M. Ryan, V. Rustgi, M. Chojkier, R. Herring, A. D. Di Bisceglie, P. Pockros, G. Subramanian, D. An, E. Svarovskaia, R. Hyland, P. Pang, W. Symonds, J. Mchutchison, A. Muir, D. Pound, M. Fried   +24 more
semanticscholar   +1 more source

Health disparities in chronic liver disease

Hepatology, EarlyView., 2022
Abstract The syndemic of hazardous alcohol consumption, opioid use, and obesity has led to important changes in liver disease epidemiology that have exacerbated health disparities. Health disparities occur when plausibly avoidable health differences are experienced by socially disadvantaged populations.
Ani Kardashian, Marina Serper, Norah Terrault, Lauren D. Nephew   +3 more
wiley   +1 more source

The efficiency and safety of anti-Helicobacter pylori therapy in patients with concomitant chronic hepatitis C [PDF]

Терапевтический архив, 2016
Aim. To evaluate the efficiency and safety of two eradication therapy (ET) regimens for Helicobacter pylori infection in patients with concomitant chronic hepatitis C (CHC) in relation to the stage of liver fibrosis (LF). Subjects and methods.
D N Andreev, I V Maev, Yu A Kucheryavyi, D T Dicheva, E V Partsvania-vinogradova   +4 more
doaj  

Molecular Evaluation of Viral load and Genotype of HCV in Acute and Chronic HCV Patients in Kirkuk City [PDF]

Kirkuk Journal of Science, 2019
The study aimed at detection of HCV load and genotypes in acute and chronic HCV patients. A cross sectional study was carried out in Kirkuk city from 15th of March 2017 to 15th of November 2017.
Israa Saadoon, Thekra Hamada, Muhannad Alazzawy   +2 more
doaj   +1 more source

Telaprevir for retreatment of HCV infection.

New England Journal of Medicine, 2011
BACKGROUND Up to 60% of patients with hepatitis C virus (HCV) genotype 1 infection do not have a sustained virologic response to therapy with peginterferon alfa plus ribavirin.
S. Zeuzem, P. Andreone, S. Pol, E. Lawitz, M. Diago, S. Roberts, R. Focaccia, Z. Younossi, G. Foster, A. Horban, P. Ferenci, F. Nevens, B. Müllhaupt, P. Pockros, R. Terg, D. Shouval, B. van Hoek, O. Weiland, R. V. van Heeswijk, S. De Meyer, D. Luo, G. Boogaerts, R. Polo, G. Picchio, M. Beumont   +24 more
semanticscholar   +1 more source

Identification of novel neutralizing determinants for protection against HCV

Hepatology, EarlyView., 2022
Identification of novel neutralizing determinants for protection against hepatitis C virus. Abstract Background and Aims HCV evasion of neutralizing antibodies (nAb) results in viral persistence and poses challenges to the development of an urgently needed vaccine.
Garazi P. Alzua, Anne F. Pihl, Anna Offersgaard, Rodrigo Velázquez‐Moctezuma, Carlos R. Duarte Hernandez, Elias H. Augestad, Ulrik Fahnøe, Christian K. Mathiesen, Henrik Krarup, Mansun Law, Jannick Prentoe, Jens Bukh, Judith M. Gottwein   +12 more
wiley   +1 more source